Towards the ideal regimen for Helicobacter pylori eradication: The search continues

Digestive and Liver Disease

Volumn 36, Issue 4, 2004, Pages 243-247

  Scarpignato, C ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; CLARITHROMYCIN; ESOMEPRAZOLE; LANSOPRAZOLE; METRONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE BISMUTH CITRATE; TINIDAZOLE; PROTON PUMP;

ANTIBIOTIC RESISTANCE; BACTERIAL SURVIVAL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG MECHANISM; ERADICATION THERAPY; FIRST PASS EFFECT; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LOW DRUG DOSE; NOTE; PATIENT COMPLIANCE; TREATMENT INDICATION; TREATMENT PLANNING; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT;

DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROTON PUMPS;

EID: 3543058738     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2004.01.004     Document Type: Article

References (67)

1. Miehlke S, Bayerdorffer E, Graham DY. Treatment of Helicobacter pylori infection. Semin Gastrointest Dis 2001;12:167-79.
2. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311-5.
3. Marshall BJ. The 1995 Albert Lasker Medical Research Award. Helicobacter pylori. The etiologic agent for peptic ulcer. J Am Med Assoc 1995;274:1064-6.
4. Tytgat GNJ, Noach LA, Rauws EAJ. Helicobacter pylori infection and duodenal ulcer disease. Gastroenterol Clin North Am 1993;22:127-39.
5. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001;15:1949-58.
6. Bazzoli F, BianchiPorro G, Bianchi MG, Molteni M, Pazzato P, Zagari RM. Treatment of Helicobacter pylori infection. Indications and regimens: an update. Dig Liver Dis 2002;34:70-83.
7. Malfertheiner P, Mégraud F, O'Morain C, Hungin APS, Jones R, Axon A, et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht-2 2000 consensus report. Aliment Pharmacol Ther 2002;16:167-80.
8. Lee J, O'Morain C. Consensus or confusion: a review of existing national guidelines on Helicobacter pylori-related disease. Eur J Gastroenterol Hepatol 1997;9:527-31.
9. Ricci V, Zarrilli R, Romano M. Voyage of Helicobacter pylori in human stomach: odyssey of a bacterium. Dig Liver Dis 2002;34:2-8.
10. Graham DY. Therapy of Helicobacter pylori: current status and issues. Gastroenterology 2000;118:S2-8.
11. Mégraud F, O'Morain C, Malfertheiner R on behalf of the Working Party of the European Helicobacter pylori Study Group. Guidelines for clinical trials in Helicobacter pylori infection. Statistical annex: statistical aspects of clinical trials in Helicobacter pylori infection. Gut 1997;41:S19-23.
12. Taylor JL, Zagari M, Murphy K, Freston JW. Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori. Arch Intern Med 1997;157:87-97.
13. Schmid CH, Whiting G, Cory D, Ross SD, Chalmers TC. Omeprazole plus antibiotics in the eradication of Helicobacter pylori infection: a meta-regression analysis of randomized, controlled trials. Am J Ther 1999;6:25-36.
14. Chiba N, Hunt RH. Drug therapy of Helicobacter pylori infection: a meta-analysis. Prog Basic Clin Pharmacol 1999;11:227-68.
15. Gene E, Calvet X, Azagra R, Gisbert JR Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther 2003;17:1137-43.
16. 2-receptor antagonists for Helicobacter pylori eradication-a meta-analysis. Lancet 1996;347:763.
17. 2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;17:1229-36.
18. Gisbert JP, Gonzalez L, Calvet X, Garcia N, Lopez T, Roque M, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000;14:1319-28.
19. Vallve M, Vergara M, Gisbert JP, Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther 2002;16:1149-56.
20. Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol 2003;17:36B-40B.
21. Wheeldon TU, Hoang TT, Phung DC, Bjorkman A, Granstrom M, Sorberg M. Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment. Aliment Pharmacol Ther 2003;18:93-100.
22. Gisbert JP, Gonzalez L, Calvet X, Roque M, Gabriel R, Pajares JM. Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy. Aliment Pharmacol Ther 2000;14:1141-50.
23. Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection-a meta-analysis. Aliment Pharmacol Ther 1999;13:857-64.
24. Van Oijen AH, Verbeek AL, Jansen JB, De Boer WA. Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies. Aliment Pharmacol Ther 2000;14:991-9.
25. Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: the QUADRATE study. Gastroenterology 2002;123: 1763-9.
26. Scarpignato C, Pelosini I. Antisecretory drugs for eradication of Helicobacter pylori: antibacterial activity and synergism with antimicrobial agents. Prog Basic Clin Pharmacol 1999;11:136-80.
27. 2-receptor antagonists. Aliment Pharmacol Ther 1993;7:27-33.
28. Freston JW. Review article: role of proton pump inhibitors in non-H. pylori-related ulcers. Aliment Pharmacol Ther 2001;15:2-5.
29. Nakao M, Malfertheiner P. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter 1998;3:21-7.
30. Scott D, Weeks D, Melchers K, Sachs G. The life and death of Helicobacter pylori. Gut 1998;43:56-60.
31. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 1997;39:5-12.
32. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989;8: 888-9.
33. Parkman HP, Urbain JL, Knight LC, Brown KL, Trate DM, Miller MA, et al. Effect of gastric acid suppressants on human gastric motility. Gut 1998;42:243-50.
34. Goddard AF, Spiller RC. The effect of omeprazole on gastric juice viscosity. Aliment Pharmacol Ther 1996;10:105-9.
35. Lind T, Megraud F, Unge P, Bayerdorffer E, O'Morain C, Spiller R, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999;116:248-53.
36. Robinson M. Dyspepsia: challenges in diagnosis and selection of treatment. Clin Ther 2001;23:1130-44.
37. Stedman CAM, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000;14:963-78.
38. McColl KEL, Kennerley P. Proton pump inhibitors-differences emerge in the hepatic metabolism. Dig Liver Dis 2002;34:461-7.
39. Thomson ABR. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole. Curr Gastroenterol Rep 2000;2:482-93.
40. Langman MJS. Which PPI? Gut 2001;49:309-10.
41. Kromer W, Horbach S, Lühmann R. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Pharmacology 1999;59:57-77.
42. Guidance on the use of proton pump inhibitors in the treatment of dyspepsia. Technology Appraisal Guidance no. 7. UK: NICE; 2000. http://www.NICE.org.uk.
43. Ulmer HJ, Beckerling A, Gatz G. Recent use of proton pump inhibitor-based triple therapies for the eradication of H. pylori: a broad data review. Helicobacter 2003;8:95-104.
44. Gisbert JP, Khorrami S, Calvet X, Pajares JM. Systematic review: rabeprazole-based therapies in Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;17:751-64.
45. Gisbert JP, Pajares JM. Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis. Dig Liver Dis 2004;36: 253-9.
46. Vergara M, Vallve M, Gisbert JP, Calvet X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;18:647-54.
47. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther 2001;15:1729-36.
48. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the maintenance of healed reflux oesophagitis. J Drug Assoc 2002;5:165-78.
49. Tonini M, Vigneri S, Savarino V, Scarpignato C. Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor. Dig Liver Dis 2001;33:600-6.
50. Scarpignato C, Pelosini I, Lamarque D. Ésoméprazole: pharmacologie et developpement d'un nouvel inhibiteur de pompe à protons. Hepato-Gastro 2003;10:277-91.
51. Eichelbaum M. Pharmacokinetic and pharmacodynamic consequences of stereoselective drug metabolism in man. Biochem Pharmacol 1988;37:93-6.
52. Tucker GT, Lennard MS. Enantiomer specific pharmacokinetics. Pharmacol Ther 1990;45:309-29.
53. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors-focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996;31:9-28.
54. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001;40:411-26.
55. Junghard O, Hassan-Alin M, Hasselgren G. The effect of the area under the plasma concentration vs. time curve and the maximum plasma concentration of esomeprazole on intragastric pH. Eur J Clin Pharmacol 2002;58:453-8.
56. Vigneri S, Tonini M, Scarpignato C, Savarino V. Improving opportunities for effective management of gastro-esophageal reflux disease. Dig Liver Dis 2001;33:720-30.
57. Kale-Pradhan PB, Landry HK, Sypula WT. Esomeprazole for acid peptic disorders. Ann Pharmacother 2002;36:655-63.
58. Scott LJ, Dunn CJ, Mallarkey G, Sharpe M. Esomeprazole. A review of its use in the management of acid-related disorders. Drugs 2002;62:1503-38.
59. Johnson DA. Review of esomeprazole in the treatment of acid disorders. Expert Opin Pharmacother 2003;4:253-64.
60. Andersson T, Röhss K, Bredberg E, Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001;15:1563-9.
61. Lind T, Rydberg L, Kylebäck A, Jonsson A, Andersson T, Hasselgren G, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000;14:861-7.
62. Kim JI, Park SH, Kim JK, Chung IS, Chung KW, Sun HS. The effects of nocturnal acid breakthrough on Helicobacter pylori eradication. Helicobacter 2002;7:331-6.
63. Miner Jr PB, Katz PO, Chen Y, Sostek MB. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98:2616-20.
64. Gillen D, Wirz AA, McColl KEL. Esomeprazole 40 mg bid produces profound 24 h acid suppression with minimal acid breakthrough. Gastroenterology 2003;124:A231.
65. Bell GD, Powell KU, Burridge SM, Bowden AN, Rameh B, Bolton G, et al. Helicobacter pylori eradication: efficacy and side effect profile of a combination of omeprazole, amoxycillin, and metronidazole compared with four alternative regimens. Q J Med 1993;86:743-50.
66. Bazzoli F, Zagari RM, Fossi S, Pozzato P, Alampi G, Simoni P, et al. Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994;6:773-7.
67. Laine L. Review article: esomeprazole in the treatment of Helicobacter pylori. Aliment Pharmacol Ther 2002;16:115-8.